Miniaturized Surgical Robotic Instruments Expand the Possibilities of Surgical Interventions

Food and Healthcare Press Releases Wednesday December 6, 2017 09:35
CALCI, Italy--6 Dec--PRNewswire/InfoQuest
  • MMI S.r.l. Unveils World's Smallest Robotic Wrist

Medical Microinstruments S.r.l. (MMI), a developer of novel robotic solutions for unmet medical needs, today reveals its robotic platform specifically designed for open microsurgery. The platform allows the surgeon to control two tiny articulated microinstruments that simplify reconstruction procedures after traumatic injuries as well as after tumor removal in soft tissue and bones, and offers the potential for improved surgical success rates and patient outcomes.

(Logo: http://mma.prnewswire.com/media/614046/MMI_Srl_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/614047/MMI_Srl_Robotic_Wrist.jpg )
Video - https://www.youtube.com/watch?v=CTg262fMap0

MMI's instruments are equipped with the smallest articulated wrist having a 3-millimeter outer diameter and tips just 150 micron in width. The wrist is the key to performing robotic microsurgery in real clinical settings and allows easy manipulation of small sutures, from 9-0 to 12-0 in size.

"Thanks to the use of advanced materials and novel microfabrication processes, we have designed the smallest articulated wrist to provide microsurgeons unique instrument dexterity and robotic precision," said Massimiliano Simi, Co-founder and VP R&D.

The surgeon operates the microinstruments while sitting at the surgical bedside and looking through the operating microscope. MMI's robotic platform captures surgeon's hand movements and a scaled-down motion is imposed on the microinstruments.

"We have developed this groundbreaking technology together with microsurgeons from the product's conception and the positive feedback and response that we've received along the way has really been overwhelming and led us to believe that we are on the right track in developing a robot by and for microsurgeons," said Hannah Teichmann, Co-founder and VP Clinical.

Prof. Marco Innocenti, Chief of Plastic and Reconstructive Microsurgery at Careggi University Hospital in Florence and MMI's Clinical Advisor, who has presented preclinical work with MMI's robot at 9th Congress of World Society for Reconstructive Microsurgery in Seoul, including 0.35mm arterial robotic anastomosis, remarked:

"In my opinion, the MMI robotic platform will push the frontier of microsurgery forward and beyond the capabilities of the human hand, thus allowing more surgeons to perform more complex procedures but also enabling supermicrosurgery, such as lymph reconstruction, for the more expert ones."

MMI's President and Co-founder, Giuseppe Maria Prisco, estimates the potential annual market opportunity to be in the order of $2.5 billion.
Related links:
http://www.mmimicro.com
Watch the company video on http://www.mmimicro.com/mmi-video
About:

Medical Microinstruments S.r.l. (MMI), founded in 2015, is based in Calci (PI), Italy. The company's mission is to help more surgeons around the world to offer more advanced procedures, while reducing costs for patients, hospitals and for society at large.

Contact:
Vanya Petrova
Relationship Manager
vanya.petrova@mmimicro.com
+39-348-5441025
Source: MMI Srl

Latest Press Release

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Tresiba(R) Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba(R) had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1] These new post-hoc...

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus...

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1 in 6 respondents had never discussed type 2 diabetes and...

Related Topics